Dr. Churilla on Impact of Health Insurance Status on Patients With HNSCC
July 5th 2016Thomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.
Expert Discusses 2-Year Nivolumab Data and Other Immunotherapy Developments in NSCLC
June 10th 2016Hossein Borghaei, DO, discusses the significance of the 2-year follow-up results of the CheckMate-057 and -017 studies, the evolving role of PD-L1 as a biomarker and others that are in development, and emerging immunotherapy agents in the field of non-small cell lung cancer.
Expert Calls for More Research in Checkpoint Blockade for Upper Tract Urothelial Cancers
December 21st 2015Compelling evidence has been presented about the various checkpoint inhibitors in bladder cancer, but, additionally there have been some provocative papers looking at genomic sequencing of upper tract compared with bladder that shows certain differences
Distinct Strategies Needed for Treating Lobular Breast Cancer
April 29th 2015Although patients with invasive lobular carcinoma are typically treated with the same therapeutic strategies as those with infiltrating ductal malignancies, ILC is emerging as a molecularly complex and distinct tumor type that suggests different approaches may be effective.
Dr. Lori Goldstein on Neoadjuvant Treatment for HER2+ Breast Cancer
February 4th 2015Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.
Dr. Fisher on Bortezomib/R-CHOP Combo for Mantle Cell Lymphoma
January 7th 2015Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.
Novel Breast Cancer Agents Aimed at Overcoming Endocrine Therapy Resistance
August 28th 2014Although advances in endocrine therapy for women with estrogen receptor (ER)-positive breast cancer have been made in recent years, de novo and acquired resistance to treatments remain important clinical problems, and efforts to identify effective modalities to overcome this challenge continue.
Dr. Movva on Molecular Profiling in Sarcoma
July 16th 2014Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses a study presented at the 2014 ASCO Annual Meeting where researchers profiled more than 1900 sarcoma specimens to try to identify potential novel treatment modalities for patients with this disease.
Angiogenesis-Targeting Agents Poised to Become a Mainstay of Gynecologic Cancer Treatment
January 3rd 2014Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer.
Unique Considerations With TKIs for Chronic Myelogenous Leukemia
October 25th 2013At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Michael Millenson, MD, Fox Chase Cancer Center, discussed considerations in selecting second- and third-generation tyrosine-kinase inhibitors for the management of chronic myelogenous leukemia